On May 16, 2018 Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, reported it will release updated data from ongoing clinical studies at the annual ASCO (Free ASCO Whitepaper) meeting at McCormick Place in Chicago, Illinois (Press release, Adaptimmune, MAY 16, 2018, View Source;p=RssLanding&cat=news&id=2349493 [SID1234526694]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Data from the ongoing pilot study of NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma (MRCLS) will be presented during an oral presentation by Dr. Sandra P. D’Angelo of the Memorial Sloan Kettering Cancer Center. GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize NY‑ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing.

In addition, data from Adaptimmune’s ongoing MAGE‑A10 pilot studies will be presented at a poster session.

Oral presentation of updated MRCLS data:

Title: Pilot Study of NY-ESO-1c259T Cells in Advanced Myxoid/Round Cell Liposarcoma
Abstract #: 3005
Oral session: Developmental Therapeutics—Immunotherapy
Date: Saturday June 2, 2018
Time: 4:24 PM – 4:36PM (CDT)
Location: McCormick Place South, Hall B1
Poster presenting MAGE-A10 safety data

Title: Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials
Abstract #: 3056
Poster session: Developmental Therapeutics—Immunotherapy
Date: Monday June 4, 2018
Time: 8:00 AM-11:30 AM (CDT)
Location: McCormick Place South, Hall A